Facebook-square Linkedin Instagram Youtube

Tandem Diabetes Care, Inc.

Johnson Fistel Announces a Class Action Lawsuit has been Filed Against Tandem Diabetes Care

Johnson Fistel, LLP notifies investors of Tandem Diabetes Care, Inc. (NASDAQ: TDM) (“Tandem Diabetes Care” or the “Company”) a securities class action lawsuit has been filed. The lawsuit seeks to recover losses on behalf of investors who acquired securities within the class period. Investors are encouraged to review the following information.

Lead Plaintiff Deadline: November 7, 2023

Class Period: August 3, 2022 and November 2, 2022

Docket #: 23-CV-01657

Please submit your information below for more information:

Tandem Diabetes Care, Inc.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.
Name(Required)
Would you like to receive future case and securities updates from Johnson Fistel, LLP via email?(Required)
Would you like to receive information about Johnson Fistel, LLP's free portfolio monitoring service?(Required)
By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, LLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

There is no cost or obligation to you.

Complaint Allegations: According to the complaint, defendants provided investors with material information concerning Tandem’s projected revenue and sales for the year ending 2022. Specifically, on August 2, 2022, Tandem estimated annual sales “to be in the range of $835 million to $845 million, which represents an annual growth of 19 percent to 20 percent compared to 2021.” Defendants provided these statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts, which caused shareholders to purchase Tandem’s securities at artificially inflated prices.

What can Investors Do: Shareholders who incurred losses during the class period, have until November 7, 2023, to move the court to become a lead plaintiff in this action.A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor’s ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistel, LLP

501 W. Broadway, Suite 800, San Diego, CA 92101

James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471

jimb@johnsonfistel.com or fjohnson@johnsonfistel.com

©2024 Johnson Fistel, LLP - All Rights Reserved.